A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial

[<sup>177</sup>Lu]Ludotadipep, which enables targeted delivery of beta-particle radiation to prostate tumor cells, had been suggested as a promising therapeutic option for mCRPC. From November 2020 to March 2022, a total of 30 patients were enrolled for single dose of [<sup>177<...

Full description

Bibliographic Details
Main Authors: Dongho Shin, Seunggyun Ha, Joo Hyun O, Seung ah Rhew, Chang Eil Yoon, Hyeok Jae Kwon, Hyong Woo Moon, Yong Hyun Park, Sonya Youngju Park, Chansoo Park, Dae Yoon Chi, Ie Ryung Yoo, Ji Youl Lee
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
metastatic castration-resistant prostate cancer
lutetium-177
PSMA
radiopharmaceutical therapy
Online Access:https://www.mdpi.com/2072-6694/14/24/6225

Internet

https://www.mdpi.com/2072-6694/14/24/6225

Similar Items